Natarajan Sethuraman, President of Research & Development at Entrada Therapeutics Inc (TRDA, Financial), executed a sale of 4,109 shares of the company on November 13, 2024. The transaction was filed through an SEC Filing. Following this transaction, the insider now owns 160,888 shares of Entrada Therapeutics Inc.
Entrada Therapeutics Inc is engaged in the development of therapies with a focus on treating muscular and neurodegenerative diseases through its proprietary Endosomal Escape Vehicle (EEV) platform. This innovative approach aims to deliver molecules to intracellular targets, addressing diseases with high unmet medical needs.
Over the past year, the insider has sold a total of 46,388 shares and has not purchased any shares. This recent sale is part of a broader trend observed at Entrada Therapeutics Inc, where there have been 21 insider sells and 6 insider buys over the past year.
On the date of the latest transaction, shares of Entrada Therapeutics Inc were priced at $20.03, resulting in a market cap of approximately $746.615 million. The company's price-earnings ratio stands at 12.55, which is below the industry median of 26.51, indicating a potentially undervalued stock relative to its peers.
Additional valuation metrics such as price-sales ratio, price-book ratio, and price-to-free cash flow are also available for further insight into the company's stock valuation through the GF Value assessment.
This insider sale could be of interest to investors tracking insider behaviors as an indicator of company performance and future stock movement. Monitoring such transactions, alongside comprehensive valuation metrics, can provide a deeper understanding of the company's financial health and market position.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
